【摘要】 目的评价碳酸司维拉姆治疗终末期肾病维持性血液透析(MHD)患者高磷血症的疗效。方法分析21例给予碳酸司维拉姆治疗的MHD患者透析前血磷、血钙、钙磷乘积和全段甲状旁腺激素(iPTH)水平,观察时间为16w。治疗期间每2周检测血清钙磷水平并根据结果调整治疗剂量。结果碳酸司维拉姆治疗2w后,患者血磷和血清钙磷乘积水平即开始明显下降。16w疗程结束时,与治疗前比较,患者血磷[(1.64±0.59)、(2.97±0.81)mmol/L,P<0.05]、钙磷乘积[(52.3±13.4)、(79.6±12.8)mg2/dL2,P<0.01]显著下降,而血浆iPTH水平和血钙水平无显著变化。结论碳酸司维拉姆能有效降低MHD患者血磷和钙磷乘积水平。更多还原

【Abstract】 Objective To evaluate the efficacy of sevelamer carbonate in treating maintenance hemodialysis(MHD)patients with hyperphosphatemia.Methods 21 MHD patients were treated with sevelamer carbonate for 16weeks.The serum level of calcium,phosphorus,calcium-phosphorus product and intact parathyroid hormone(iPTH)were detected every 2 weeks during treatment and the dose was adjusted according to the testing data.Results After two weeks of treatment with sevelamer carbonate,serum phosphorus and serum calcium-phosphorus product levels decreased.By the end of treatment,compared with before treatment,the level of serum phosphorus[(1.64±0.59)vs(2.97±0.81)mmol/L,P <0.05]and serum calcium-phosphorus product[(52.3±13.4)vs(79.6±12.8)mg2/dL2,P <0.01〗were significantly decreased,while the serum level of calcium and serum iPTH had no significant change.Conclusion Sevelamer carbonate can effectively reduce serum level of phosphorus and calcium-phosphorus product in MHD patients.更多还原